Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products
Alteogen Inc. has signed an option and license agreement with Novartis granting Novartis rights to develop and commercialize subcutaneous formulations using Alteogen’s Hybrozyme™ platform. This marks Alteogen’s fourth licensing agreement in 2026, emphasizing its platform expansion.
Alteogen Novartis licensing agreement Hybrozyme biopharmaceutical
Linked Entities
Contributing Articles
South Korea exports surpass annual record as AI chip boom drives shipments
Investing.com —
Advanced Shipping & Trading – WEEKLY SHIPPING MARKET REPORT WEEK 36 2026
Hellenic Shipping News —
South Korea to double 2027 budget for farm solar, agrivoltaics
PV Magazine Solar —
Yang Ming and Hanwha Ocean Sign Contract for Six New 13,000 TEU Class LNG Dual-Fuel Container Vessels
Hellenic Shipping News —
Hanwha joins Korea LNG expansion as AI power demand surges and SE Asia shifts
Hellenic Shipping News —
Hanwha Aerospace nearing deal to export Chunmoo rocket launchers to Croatia: sources
Yonhap News —
S. Korea, British chip firm Arm open training school in southwestern city of Gwangju
Yonhap News —
South Korea says chip investments under discussion with US amid tariff concerns
Investing.com —
State-run firms' restructuring aimed at reform, not cost cuts: official
Yonhap News —
S. Korean firms unveil plans for gov't-led AI project
Yonhap News —